Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › cardiotoxicity

Cardiotoxicity

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cardiotoxicity

2 trials tracked for cardiotoxicity.

2Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 1 2
  1. Phase 1 Staccato Prochlorperazine Thorough QT/QTc Completed
  2. Phase 1 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Oncology Cohort
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.
Frontiers Apr 23, 2026
Meta-analysis finds beta-blockers may reduce cardiotoxicity risk during cancer therapy
Cardiology Meta-analysis
Meta-analysis finds beta-blockers may reduce cardiotoxicity risk during cancer therapy Heart-Protecting Meds Show Promise for Cancer Patients
A meta-analysis of 19 RCTs in patients receiving anthracyclines and/or trastuzumab found beta-blockers improved LVEF (WMD=2.19) and reduced…
Two specific heart medications stand out as the most effective shields against heart damage caused by powerful cancer treatments.
Frontiers Apr 13, 2026